Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
PLoS One ; 7(10): e47542, 2012.
Article in English | MEDLINE | ID: mdl-23094059

ABSTRACT

BACKGROUND: Mortality in the first months of antiretroviral therapy (ART) is a significant clinical problem in sub-Saharan Africa. To date, no post-mortem study has investigated the causes of mortality in these patients. METHODS: HIV-positive adults who died as in-patients at a Johannesburg academic hospital underwent chart-review and ultrasound-guided needle autopsy for histological and microbiological examination of lung, liver, spleen, kidney, bone marrow, lymph node, skin and cerebrospinal fluid. A clinico-pathologic committee considered all available data and adjudicated immediate and contributing causes of death. RESULTS: Thirty-nine adults were enrolled: 14 pre-ART, 15 early-ART (7-90 days), and 10 late-ART (>90 days). Needle sampling yielded adequate specimen in 100% of kidney, skin, heart and cerebrospinal fluid samples, 97% of livers and lungs, 92% of bone marrows, 87% of spleens and 68% of lymph nodes. Mycobacterial infections were implicated in 69% of deaths (26 of 27 of these due to M. tuberculosis), bacterial infections in 33%, fungal infections in 21%, neoplasm in 26%, and non-infectious organ failure in 26%. Immune reconstitution inflammatory syndrome (IRIS) was implicated in 73% of early-ART deaths. Post-mortem investigations revealed previously undiagnosed causes of death in 49% of cases. Multiple pathologies were common with 62% of subjects with mycobacterial infection also having at least one other infectious or neoplastic cause of death. CONCLUSIONS: Needle biopsy was efficient and yielded excellent pathology. The large majority of deaths in all three groups were caused by M. tuberculosis suggesting an urgent need for improved diagnosis and expedited treatment prior to and throughout the course of antiretroviral therapy. Complex, unrecognized co-morbidities pose an additional challenge.


Subject(s)
Antiretroviral Therapy, Highly Active , Bacterial Infections/mortality , HIV Infections/mortality , Immune Reconstitution Inflammatory Syndrome/mortality , Tuberculosis, Pulmonary/mortality , Adult , Autopsy , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Bacterial Infections/pathology , Bacterial Infections/virology , Biopsy, Needle , Bone Marrow/drug effects , Bone Marrow/pathology , Bone Marrow/virology , Cause of Death , Female , HIV/drug effects , HIV/growth & development , HIV Infections/drug therapy , HIV Infections/pathology , HIV Infections/virology , Humans , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/pathology , Immune Reconstitution Inflammatory Syndrome/virology , Kidney/drug effects , Kidney/pathology , Kidney/virology , Liver/drug effects , Liver/pathology , Liver/virology , Lung/drug effects , Lung/pathology , Lung/virology , Lymph Nodes/drug effects , Lymph Nodes/pathology , Lymph Nodes/virology , Male , Middle Aged , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development , Skin/drug effects , Skin/pathology , Skin/virology , South Africa/epidemiology , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/microbiology , Tuberculosis, Pulmonary/pathology , Tuberculosis, Pulmonary/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...